Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
2090 studies found for:    Bevacizumab
Show Display Options
Rank Status Study
1 Active, not recruiting Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma
Condition: Melanoma
Interventions: Drug: Bevacizumab Plus Ipilimumab Cohort 1;   Drug: Bevacizumab Plus Ipilimumab Cohort 2;   Drug: Bevacizumab Plus Ipilimumab Cohort 3;   Drug: Bevacizumab Plus Ipilimumab Cohort 4
2 Completed
Has Results
A Phase 2 Evaluation of Anti-VEGF Therapy for Diabetic Macular Edema: Bevacizumab (Avastin)
Condition: Diabetic Retinopathy
Interventions: Procedure: Laser Photocoagulation;   Drug: Bevacizumab
3 Not yet recruiting Induction Discontinuation Trial of Emactuzumab Following Paclitaxel and Bevacizumab in Patients With Platinum-Resistant, Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer - REDIRECT
Condition: Malignant Neoplasms of Female Genital Organs
Interventions: Drug: Paclitaxel;   Drug: Bevacizumab;   Drug: Emactuzumab
4 Recruiting Bevacizumab, Temsirolimus Alone and in Combination With Valproic Acid or Cetuximab in Patients With Advanced Malignancy and Other Indications
Condition: Advanced Cancers
Interventions: Drug: Temsirolimus;   Drug: Bevacizumab;   Drug: Valproic Acid;   Drug: Cetuximab
5 Completed Bevacizumab, Erlotinib and Capecitabine for Advanced Pancreatic Cancer
Condition: Pancreatic Cancer
Interventions: Drug: Bevacizumab;   Drug: Erlotinib;   Drug: Capecitabine;   Radiation: Radiation Therapy
6 Completed Phase II Pilot Study of Visudyne® Photodynamic Therapy (PDT) (Low and Very Low Fluence) Combined With Bevacizumab.
Condition: Macular Degeneration
Interventions: Drug: Verteporfin Photodynamic Therapy (Low Fluence) and bevacizumab;   Drug: Verteporfin Photodynamic Therapy (Very Low Fluence) and bevacizumab;   Drug: Verteporfin Photodynamic Therapy (SHAM) and bevacizumab
7 Completed
Has Results
A Phase II Trial of Cetuximab and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer
Conditions: Head and Neck Cancer;   Squamous Cell Carcinoma
Interventions: Drug: Cetuximab;   Drug: Bevacizumab
8 Completed Results of Adjunctive Intraoperative Bevacizumab Injection on Trabeculectomy Outcome
Condition: Glaucoma
Interventions: Drug: Bevacizumab;   Drug: Mitomycin C
9 Completed
Has Results
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
Conditions: Adult Glioblastoma;   Adult Gliosarcoma;   Recurrent Adult Brain Tumor
Interventions: Drug: irinotecan hydrochloride;   Biological: bevacizumab;   Drug: temozolomide
10 Unknown  Intralesional Bevacizumab Injection on Primary Pterygium
Conditions: Pterygium;   Inflammation
Interventions: Drug: Intralesional injection of bevacizumab;   Drug: Topical antihistamine and vasoconstrictor
11 Completed
Has Results
Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Doxorubicin and cyclophosphamide (AC) + bevacizumab;   Drug: Docetaxel (T) + bevacizumab;   Drug: Docetaxel, doxorubicin, cyclophosphamide (TAC) + bevacizumab;   Drug: Docetaxel, carboplatin, trastuzumab (TCH) + bevacizumab;   Drug: Bevacizumab and trastuzumab maintenance therapy;   Drug: Bevacizumab maintenance therapy
12 Active, not recruiting Dose Escalation of Bevacizumab With Ambulatory Blood Pressure Monitoring in Patients With Advanced Non-squamous NSCLC
Condition: Advanced Non-squamous Non-Small Cell Lung Cancer
Interventions: Drug: Carboplatin and Pemetrexed with Bevacizumab 7.5 mg/kg;   Drug: Carboplatin and Pemetrexed with Bevacizumab 15 mg/kg
13 Completed Neoadjuvant TAC Plus or Minus Bevacizumab(AVF3299)
Condition: Breast Cancer
Interventions: Drug: Bevacizumab 7.5 and TAC;   Drug: Placebo 7.5 and Docetaxel, Doxorubicin, and Cyclophosphamide (TAC);   Drug: Bevacizumab 15 and TAC;   Drug: Placebo 15 and TAC
14 Active, not recruiting Bevacizumab, Irinotecan and Temozolomide for Relapsed or Refractory Neuroblastoma
Condition: Neuroblastoma
Intervention: Drug: Bevacizumab, Irinotecan and Temozolomide
15 Recruiting Pilot Study of Zirconium-89 Bevacizumab Positron Emission Tomography for Imaging Angiogenesis in Patients With Inflammatory Breast Carcinoma Receiving Preoperative Chemotherapy
Condition: Inflammatory Breast Carcinoma
Interventions: Drug: 89Zr-bevacizumab;   Procedure: FDG-PET/CT;   Procedure: MRI scan;   Procedure: Tumor biopsies
16 Recruiting Niraparib and/or Niraparib-Bevacizumab Combination Against Bevacizumab Alone in HRD Platinum Sensitive Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Drug: Niraparib;   Drug: Bevacizumab
17 Active, not recruiting Sorafenib Tosylate, Bevacizumab, Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer
Conditions: Recurrent Colon Carcinoma;   Recurrent Rectal Carcinoma;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer
Interventions: Biological: Bevacizumab;   Drug: Fluorouracil;   Drug: Irinotecan Hydrochloride;   Drug: Leucovorin Calcium;   Drug: Sorafenib Tosylate
18 Unknown  Preoperative Injection of Bevacizumab Prior to Vitreoretinal Surgery in Diabetic Tractional Retinal Detachment
Conditions: Intravitreal Bevacizumab Injection;   Pars Plana Vitrectomy;   Tractional Retinal Detachment;   Diabetic Retinopathy
Intervention: Drug: Bevacizumab
19 Active, not recruiting Tivantinib and Bevacizumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Condition: Solid Neoplasm
Interventions: Biological: Bevacizumab;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Tivantinib
20 Not yet recruiting Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN)
Conditions: Gestational Trophoblastic Neoplasia;   Choriocarcinoma;   Placental Site Trophoblastic Tumor;   Epithelioid Trophoblastic Tumor
Interventions: Drug: TRC105;   Drug: Bevacizumab

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years